Laden…
2-[1-(aminomethyl)cyclohexyl]acetic acid
Gabapentin is an anticonvulsant and sedative primarily used for the treatment of neuropathic pain and epilepsy. It works by binding to the α2δ subunit of voltage-gated calcium channels, thereby modulating the release of excitatory neurotransmitters. The substance has a moderate risk profile, particularly when taken concurrently with other central depressants. Gabapentin is also used off-label for various indications.
Class
Depressiva
Pharmacological context
Mechanism
Gabapentin ist ein strukturelles GABA-Analogon, bindet jedoch NICHT an...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: 2-[1-(aminomethyl)cyclohexyl]acetic acid
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Gabapentin ist ein strukturelles GABA-Analogon, bindet jedoch NICHT an GABA-Rezeptoren. The primary mechanism of action ist die hochaffine Bindung an die α2δ-1-Untereinheit (Hilfsprotein) spannungsgesteuerter Kalziumkanäle (VGCCs, insbesondere Cav2.1/P/Q-Typ und Cav2.2/N-Typ). Diese Bindung reduziert den präsynaptischen Kalziumeinstrom und verringert die Freisetzung exzitatorischer Neurotransmitter (Glutamat, Substanz P, Noradrenalin). Dies erklärt die antikonvulsive, analgetische und anxiolytische Wirkung. Dopaminerge Effekte bei hohen Dosen (Euphorie, Sedierung) werden indirekt über die Modulation exzitatorischer Schaltkreise vermittelt. Gabapentin besitzt keine direkte Aktivität an GABA-A- oder GABA-B-Rezeptoren, ionotropen Glutamatrezeptoren oder Natriumkanälen. Die klinisch relevante Interaktion mit Opioiden ergibt sich aus komplementärer Analgesie durch unterschiedliche Zielstrukturen — und erklärt die gefährliche synergistische respiratory depression bei Kombination.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 600–1200 mg
Total duration 8–12 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 300 mg |
| Reported | 600–1200 mg |
| Strong | 2400 mg |
Oral
Onset
1–2 hours
Peak
2–3 hours
Total duration
8–12 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.